BELMONT, Calif., Sept. 21 /PRNewswire/ -- Ventus Medical, a privately-held medical device company focused on improving the lives of patients with sleep-disordered breathing, today announced that the company's PROVENT(R) Sleep Apnea Therapy received the Runners-Up Award in The Wall Street Journal 2009 Technology Innovation Awards, Medical Devices category. The results were published in the September 14, 2009 edition of The Wall Street Journal.
"We are excited to be recognized by The Wall Street Journal for our PROVENT Sleep Apnea Therapy," said John McCutcheon, President and Chief Executive Officer at Ventus Medical. "We are proud of this innovative treatment and the potential benefit it brings to the more than 50 million Americans who have obstructive sleep apnea and those not satisfied with standard therapies. We continue our commitment to developing innovative solutions for people affected by sleep-disordered breathing."
According to The Wall Street Journal, winners were selected from nearly 500 nominations across numerous categories from nearly 20 countries. Of those, more than 180 nominations cleared preliminary screening and were passed on for review by a panel of judges comprised of research institutions, venture capital firms and other companies. Judges evaluated whether innovations were truly groundbreaking and also looked at whether their application would be particularly useful in a time of economic hardship. Only seven percent of entries screened by the judges received an award.
About PROVENT Therapy
PROVENT Therapy is a prescription device indicated for the treatment of obstructive sleep apnea (OSA). It is an easy to use and disposable treatment that works across mild, moderate, and severe OSA. The treatment utilizes nasal expiratory positive airway pressure and has been clinically shown to reduce sleep apnea. It incorporates a novel MicroValve design that is placed over the nostrils and secured with hypoallergenic adhesive. During inhalation, the valve opens allowing nearly unobstructed airflow, and during exhalation, the valve closes, limiting airflow through two small openings, which increases expiratory pressure, helping to keep the airway open.
Currently, PROVENT Therapy is available in limited locations in the United States with the assistance and support of professional sleep physicians. PROVENT Therapy may not be appropriate for everyone. For more information, please visit www.ProventTherapy.com.
Sleep-disordered breathing broadly refers to a group of disorders characterized by abnormalities of breathing pattern (such as stopping breathing) or the abnormal reduction in the volume of breaths while sleeping. OSA is the most common type of sleep-disordered breathing. An estimated 50 million people in the United States suffer from OSA, which occurs when the upper airway (near the back of the mouth) collapses during sleep, obstructing the airway and preventing air from entering the lungs. OSA is caused by multiple factors, including sleep-induced relaxation of the throat muscles and tongue, enlarged tonsils and adenoids, an abnormally small airway diameter in the back of the mouth and throat, and extra soft tissue in and around the throat due to being overweight.
About Ventus Medical
Ventus Medical is a medical device company focused on improving the lives of patients with sleep-disordered breathing. Located in Belmont, California, Ventus Medical has developed and markets PROVENT Therapy, an innovative, clinically-proven treatment for OSA. Existing OSA solutions do not always meet patients' needs. Through truly innovative technology, solid clinical evidence, and a focus on the patient, Ventus Medical seeks to deliver consumer-preferred, physician-recommended solutions. The company is privately-held and funded by De Novo Ventures, Mohr Davidow Ventures, and Johnson & Johnson Development Corporation.
|SOURCE Ventus Medical, Inc.|
Copyright©2009 PR Newswire.
All rights reserved